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Topical non-steroidal anti-inﬂammatory drugs (NSAIDs) are recommended in international and national
guidelines as an early treatment option for the symptomatic management of knee and hand osteo-
arthritis (OA), and may be used ahead of oral NSAIDs due to their superior safety proﬁle. The European
Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment
algorithm recommends topical NSAIDs for knee OA in addition to the pharmacological background of
symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) and rescue analgesia with paracetamol
and non-pharmacological treatment, if the patient is still symptomatic. Topical NSAIDs have a moderate
effect on pain relief, with efﬁcacy similar to that of oral NSAIDs, with the advantage of a better risk:
beneﬁt ratio. In real-life studies, topical and oral NSAIDs demonstrate an equivalent effect on knee pain
over 1 year of treatment, with fewer adverse events due to lower systemic absorption of topical NSAIDs
compared with oral NSAIDs. As a result, topical NSAIDs may be the preferred treatment option, especially
in OA patients aged Z75 years, and those with co-morbidities or at an increased risk of cardiovascular,
gastrointestinal, or renal side effects. Furthermore, using topical NSAIDs in inﬂammatory rheumatic diseases
leads to a 40% reduction in the need for concomitant oral NSAIDs. When selecting a topical NSAID,
absorption and bioavailability are important because of heterogeneity among topical drug formulations.
Molecules like etofenamate have a bioavailability of 420% and evidence for accumulation in synovial
tissues, with efﬁcacy demonstrated as improvement in pain and function in real-life studies of OA patients.
Diclofenac also shows good efﬁcacy alongside evidence that diclofenac accumulates in the synovium.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm
recommends topical non-steroidal anti-inﬂammatory drugs
(NSAIDs) for knee osteoarthritis (OA) in addition to background
pharmacological treatment with symptomatic slow-acting drugs
for osteoarthritis (SYSADOAs) and rescue analgesia with para-
cetamol and non-pharmacological treatment, if the patient is still
symptomatic [1]. Topical NSAIDs are universally recommended
across international and national guidelines for knee and hand OA
(Table 1), generally ahead of oral NSAIDs or opioids for pain relief,
due to their superior safety proﬁle [1–5]. Topical NSAIDs have a
moderate effect on pain relief, with efﬁcacy similar to that of oralr HS Journals, Inc. This is an open
tory drug; OA, osteoarthritis;
rthritis.
nnou).NSAIDs, but with a much better safety proﬁle because of the lower
systemic absorption [6]. The American College of Rheumatology
(ACR) strongly recommends the use of topical rather than oral
NSAIDs among people aged 75 years or older with knee OA [3],
who often have co-morbidities or increased risk of cardiovascular,
gastrointestinal (GI), or renal side effects. Lastly, ACR and NICE
clinical guidelines recommend topical NSAIDs as ﬁrst-line treat-
ment for hand OA [3,5].Examination of the evidence base for topical NSAID efﬁcacy
The efﬁcacy of topical NSAIDs has been established in random-
ized controlled trials (RCTs) and meta-analyses [6–9]. A 2011
comparative effectiveness review found comparable efﬁcacy for
topical and oral NSAIDs for knee OA. Head-to-head trials of up to
12 weeks' treatment showed no difference between topical and oral
NSAIDs for efﬁcacy in patients with localized OA, with lower risk of
GI adverse events (AEs) but a higher risk of dermatological AEs withaccess article under the CC BY-NC-ND license
Table 1
Recommendations for the use of topical non-steroidal anti-inﬂammatory drugs (NSAIDs) for knee and hand osteoarthritis
Guideline committee Recommendation for topical NSAIDs
European Society for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis (ESCEO)
Recommended with paracetamol or SYSADOAs for knee OA when patients have
insufﬁcient pain relief
European League Against Rheumatism (EULAR) Topical NSAIDs have efﬁcacy in knee OA and are safe
American College of Rheumatology (ACR) Conditionally recommended for initial therapy in hand and knee OA
Osteoarthritis Research Society International (OARSI) Appropriate for individuals with knee OA only (with or without co-morbidities)
National Institute for Health and Care Excellence (NICE) Consider ahead of oral NSAIDs or opioids; can be used with paracetamol in knee and
hand OA
OA, osteoarthritis; SYSADOAs, symptomatic slow-acting drugs for osteoarthritis.
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difference in efﬁcacy between topical and oral NSAIDs, but superior
efﬁcacy with topical NSAIDs compared with placebo for reducing
pain due to chronic musculoskeletal conditions [10]. The most data
available was for topical diclofenac in OA, where the number
needed to treat (NNT) for at least 50% pain relief over 8–12 weeks
compared with placebo was 6 for the solution and 11 for the gel
formulation. The magnitude of the beneﬁt for topical diclofenac in
solution is similar to that found for oral NSAIDs (NNT: 5–8) in
studies with similar duration and outcomes [11]. While there were
insufﬁcient data to compare the individual topical NSAIDs, other
than diclofenac, with placebo, the NNT for all topical NSAIDs was
estimated at 10 (range: 7–17) [10]. In RCTs of topical diclofenac
application for 4–8 weeks, signiﬁcantly greater changes from base-
line in Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) subscales for pain, stiffness, and physical function
were found compared with placebo, as well as for patient global
assessment [12–14]. While similar effects on knee pain and dis-
ability, measured as global WOMAC score, have been observed for
both oral and topical ibuprofen after 12 months' therapy in an RCT
of 282 people aged over 50 years with knee pain [15].
An increase in local AEs, mostly mild skin reactions, was noted
with topical diclofenac, with no increase in serious AEs and no
increase in GI events compared with placebo [10]. While there are
relatively few high-quality RCTs of interventions for hand OA
published [16], topical diclofenac gel is demonstrated to be
effective in primary hand OA with a reduction in pain intensity
score of 42–45% and global rating of disease of up to 40% reported
after 4–6 weeks' treatment [17].
Recent studies of topical ketoprofen formulations have failed to
show a beneﬁt for ketoprofen over the topical placebo treatment
[18,19]. Surprisingly, in an active-control trial, both topical ketoprofen
and ketoprofen-free vehicle were found to be superior to oral placebo
and non-inferior to celecoxib for reducing knee OA pain at 12 weeks
[19]. Both topical ketoprofen and the ketoprofen-free vehicle had a
similar effect on reduction in WOMAC pain score at 12 weeks
(at approximately 40% reduction compared with 29% for placebo).
In another trial, ketoprofen was found to be inferior to ketoprofen-
free gel in relieving moderate OA knee pain and improving joint
function [18]. These reports are not totally incongruous with the
evidence base, as a meta-analysis of RCTs in OA has reported a high
placebo effect for pain, stiffness, and self-reported function [20]. In
studies of topical NSAIDs, transdermal delivery of a placebo and
previous pain relief experience with oral NSAIDs may provide an
expectation for pain relief in participating patients that has poten-
tially inﬂuenced the failure of many topically applied NSAIDs to
demonstrate clinically signiﬁcant beneﬁt compared with topical
placebo [21].
Evidence from real-life studies
The ESCEO algorithm recommends topical NSAIDs for knee OA in
addition to background pharmacological treatment with SYSADOAsif the patient is still symptomatic [1], yet few studies have reported
on the efﬁcacy of the combination of topical NSAID plus SYSADOA.
A real-life prospective, non-controlled study conducted in Russia
recruited nearly 4000 patients with OAwho were prescribed topical
diclofenac (1% aerosol formulation, 3–4 times/day) for 2 weeks plus
patented crystalline glucosamine sulfate (pCGS) formulated either
as an intramuscular injection (ampule: 200 mg/ml, 2 ml 3 times/
week) for 4 weeks or as an oral suspension (powder 1500 mg once/
day) for 8 weeks [22]. After 8 weeks the median pain severity
assessed on a numeric rating scale (NRS) had decreased signiﬁcantly
from 0.8 to 0.2 (interquartile range: 70.2; p o 0.001).
Few real-life trials have studied the use of topical NSAIDs over
time periods longer than 12 weeks. A study of patients (aged Z50
years) with chronic knee pain treated in primary care practice in the
United Kingdom, recruited patients either into a randomized trial or
patient preference study for up to 2 years [15]. In the controlled
trial, patients (n ¼ 282) were randomized to receive topical or oral
NSAID treatment (approximately 1:1), while in the preference study
three-quarters of patients (n ¼ 303) chose to receive topical NSAID
treatment. Overall, the study found that topical and oral NSAIDs
were equivalent for effect on knee pain over 1 year, with no
signiﬁcant difference in changes in global WOMAC scores at 12
months for topical and oral NSAIDs. There was a slight increase in
AEs and number of patients changing medication due to AEs for the
oral NSAID group. In the topical group, more participants had
chronic pain grade III or IV at 3 months, and more participants
changed treatment due to ineffectiveness. The results were consis-
tent across the randomized trial and patient preference study [15].
The use of topical NSAIDs may have a treatment-sparing effect
on the use of oral NSAIDs in moderate-severe rheumatic disease.
A real-life study of over 3500 patients with a range of rheumatic
diseases, including OA (n ¼ 1288), showed an average 40%
reduction in the required dose of oral NSAIDs with the addition
of topical etofenamate over 2–4 weeks in inﬂammatory rheumatic
disease [23]. OA patients also reported a 46% improvement in pain
and 34% improvement in function with topical etofenamate treat-
ment. Lowering the oral NSAID dose due to addition of etofena-
mate led to a signiﬁcant reduction in reporting of AEs, in particular
a 420% reduction in AEs of the GI tract [23].Bioavailability of topical NSAIDs
As the largest human organ, the skin forms a barrier between
the organism and the environment. Its fundamental physiological
functions include both the regulation of body temperature
(homeostasis) and the regulation of water and substance
exchange. The uppermost layer, the stratum corneum, forms the
most important barrier to absorption in the epidermis, with a high
lipid and very low water content, and is the rate-limiting step for
epidermal drug transport [24].
There are great variations in the permeability of the skin to
different substances. While both purely hydrophilic and purely
Table 2
Bioavailability of topical NSAIDs and analgesics [25]
Active agent Active agent
concentration (%)
Per-cutaneous
absorption (%)
Benzydamine 3 1–4
Bufexamac 5 4–7
Diclofenac 1 6
Etofenamate 5 21
Flufenamic acid 2.5 2
Ibuprofen 5 5
Indomethacin 1 1
Ketoprofen 2.5 1
Salicylic acid 2 1–23
F. Rannou et al. / Seminars in Arthritis and Rheumatism 45 (2016) S18–S21S20lipophilic substances are barely absorbed through the skin, there
are very high absorption rates for predominantly lipophilic sub-
stances with a certain residual hydrophilia. The bioavailability of
etofenamate following topical application is very high at 420%
compared with 1–7% for other topical NSAIDs (Table 2) [25]. The
physicochemical characteristics of etofenamate, i.e., pronounced
lipophilia and residual hydrophilia, allow good penetration
through the skin, irrespective of the pH value of the individual
layers, and accumulation in the inﬂamed tissues [26].Evidence of accumulation in target tissues
Penetration through the skin and accumulation of the active
ingredient in the desired target tissues are important for the
efﬁcacy of topical NSAIDs. At the same time, low concomitant
plasma levels will ensure low systemic burden and minimize
systemic AEs. Studies with topical diclofenac have shown that
the level attained in blood is 0.4–2.2% of the maximum serum
concentration achieved with oral diclofenac, resulting in signiﬁ-
cantly lower systemic exposure [27].
Following topical application, studies in humans demonstrate
that plasma levels of etofenamate are 10 times lower than tissue
levels in fasciae, muscles, and periosteum [28]. A study has
measured the distribution of etofenamate in intra-articular and
periarticular tissue following the application of 10% etofenamate
gel to the affected knee 3 times daily on 3 days before surgery on
the anterior cruciate ligament (n ¼ 13) [29]. Samples of the
following tissues and ﬂuids were taken during the operation:
blood, synovial ﬂuid, synovial membrane, muscle, patella, condyle
of the femur, infrapatellar fat pad, patellar ligament, and cruciate12
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Fig. Fenamate concentration (etofenamate plus ﬂufenamic acid) in intraarticular and per
etofenamate gel. (Adapted from Walde [29].)ligament. In 12 h following application, the lowest concentrations
(approximately 20 ng/ml) of etofenamate and ﬂufenamic acid, a
metabolite, were found in the blood and synovial ﬂuid, while the
highest concentrations (125–327 ng/ml) were found in the syno-
vial membrane, muscle, patella, patellar tendon, and cruciate
ligament (Fig.) [29].
In a recent trial, patients with joint effusions and scheduled for
total knee arthroplasty (TKA) received diclofenac sodium 4% spray
gel with 2- or 3-times daily application for 3 days prior to surgery
(n ¼ 39) [30]. Within 8 h of the last application, TKA was
conducted and the diclofenac concentrations were found to be
10–20-fold higher in the synovial tissue in a dose-dependent
manner, compared with the synovial ﬂuid and blood plasma
concentration (Table 3). Treatment-related AEs were limited to
skin reactions recorded in 2 patients.
The potential beneﬁts (and harms) of topically applied NSAIDs
at the chondrocyte level are yet to be fully elucidated. In vitro
studies have shown that several NSAIDs (such as sodium salicylate
and indomethacin) inhibit the synthesis of cartilage matrix com-
ponents, whereas others (such as aceclofenac and meloxicam)
increase matrix synthesis and protect chondrocytes against apop-
tosis [31]. Studies in animal models of OA show diverse effects of
the same NSAIDs on articular cartilage in different animal models.
Nonetheless, clinical data support a local mechanism of action for
topical NSAIDs at the application site [32].Conclusions
Topical NSAIDs are recommended in international and national
guidelines, including the ESCEO treatment algorithm, as an early
treatment option for the symptomatic management of knee and
hand OA. While the level of evidence for the effectiveness of
topical NSAIDs is lower than with other treatments due to a lack of
appropriate studies, the effectiveness of topical NSAIDs is com-
parable to oral NSAIDs with the advantage of a superior risk:
beneﬁt ratio. The quasi-effect size of NNT for topical diclofenac in
knee OA over 8–12 weeks was calculated as 6 for the solution and
11 for the gel formulation.
In real-life studies, topical and oral NSAIDs demonstrate an
equivalent effect on knee pain over 1 year of treatment, with fewer
AEs recorded for topical NSAIDs and fewer patients changing
medication due to AEs with topical NSAIDs compared with oral
treatments. Given the option, three-quarters of patients chose to
use a topical NSAID rather than an oral NSAID. Furthermore, using326.5
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iarticular tissue of the knee joint approximately 12 h after the last application of 10%
Table 3
Penetration of topical diclofenac sodium (4% spray gel) into the synovial tissue and
synovial ﬂuid of the knee [30]
Median diclofenac
concentration (range)
Diclofenac (2  40 mg/
day) (n ¼ 20)
Diclofenac (3  40 mg/
day) (n ¼ 19)
Plasma (ng/ml) 3.9 (1.3–302.2) 4.1 (1.1–23.0)
Synovial ﬂuid (ng/ml) 2.6 (0.4–408.5) 2.8 (0.2–47.1)
Synovial tissue (ng/g) 36.2 (1.2–1232.0) 42.8 (0.8–594.0)
F. Rannou et al. / Seminars in Arthritis and Rheumatism 45 (2016) S18–S21 S21topical NSAIDs in inﬂammatory rheumatic diseases leads to a 40%
reduction in the need for concomitant oral NSAIDs, with a
reduction in the reporting of GI side effects.
When selecting a topical NSAID, absorption, that is to say
bioavailability, matters. It should be noted that there is some
heterogeneity between different topical drug formulations. Mole-
cules like etofenamate have a bioavailability of greater than 20%,
and evidence for accumulation in synovial tissues, with efﬁcacy
demonstrated as improvement in pain and function in real-life
studies of OA patients. Good data also exist for the effectiveness of
diclofenac in hand and knee OA alongside evidence that diclofenac
accumulates in the synovium. Conversely, recent studies fail to
demonstrate a beneﬁt for topical ketoprofen and demonstrate a
high placebo effect for topical sham treatments used in these
studies.
For safety reasons, topical NSAIDs may be used in preference to
oral NSAIDs due to their lower peak plasma concentration, and
consequent lower propensity to cause unwanted side effects. Due
to their non-inferiority and superior safety proﬁle, topical NSAIDs
may be the preferred treatment option, especially in OA patients
aged 75 years or older, and those with co-morbidities or at an
increased risk of cardiovascular, GI, or renal side effects.Acknowledgments
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